Cargando…

Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells

BACKGROUND: Despite current therapies, lung cancer remains a global issue and requires the creation of novel treatment methods. Recent research has shown that biguanides such as metformin (MET) and silibinin (SIL) have a potential anticancer effect. As a consequence, the effectiveness of MET and SIL...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmani-Javan, Elnaz, Jafari-Gharabaghlou, Davoud, Bonabi, Esat, Zarghami, Nosratollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471189/
https://www.ncbi.nlm.nih.gov/pubmed/37664043
http://dx.doi.org/10.3389/fonc.2023.1193708
_version_ 1785099823915991040
author Salmani-Javan, Elnaz
Jafari-Gharabaghlou, Davoud
Bonabi, Esat
Zarghami, Nosratollah
author_facet Salmani-Javan, Elnaz
Jafari-Gharabaghlou, Davoud
Bonabi, Esat
Zarghami, Nosratollah
author_sort Salmani-Javan, Elnaz
collection PubMed
description BACKGROUND: Despite current therapies, lung cancer remains a global issue and requires the creation of novel treatment methods. Recent research has shown that biguanides such as metformin (MET) and silibinin (SIL) have a potential anticancer effect. As a consequence, the effectiveness of MET and SIL in combination against lung cancer cells was investigated in this study to develop an effective and novel treatment method. METHODS: Niosomal nanoparticles were synthesized via the thin-film hydration method, and field emission scanning electron microscopy (FE-SEM), Fourier transform infrared (FTIR), atomic force microscopy (AFM), and dynamic light scattering (DLS) techniques were used to evaluate their physico-chemical characteristics. The cytotoxic effects of free and drug-loaded nanoparticles (NPs), as well as their combination, on A549 cells were assessed using the MTT assay. An apoptosis test was used while under the influence of medication to identify the molecular mechanisms behind programmed cell death. With the use of a cell cycle test, it was determined whether pharmaceutical effects caused the cell cycle to stop progressing. Additionally, the qRT-PCR technique was used to evaluate the levels of hTERT, BAX, and BCL-2 gene expression after 48-h medication treatment. RESULTS: In the cytotoxicity assay, the growth of A549 lung cancer cells was inhibited by both MET and SIL. Compared to the individual therapies, the combination of MET and SIL dramatically and synergistically decreased the IC50 values of MET and SIL in lung cancer cells. Furthermore, the combination of MET and SIL produced lower IC50 values and a better anti-proliferative effect on A549 lung cancer cells. Real-time PCR results showed that the expression levels of hTERT and BCL-2 were significantly reduced in lung cancer cell lines treated with MET and SIL compared to single treatments (p< 0.001). CONCLUSION: It is anticipated that the use of nano-niosomal-formed MET and SIL would improve lung cancer treatment outcomes and improve the therapeutic efficiency of lung cancer cells.
format Online
Article
Text
id pubmed-10471189
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104711892023-09-01 Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells Salmani-Javan, Elnaz Jafari-Gharabaghlou, Davoud Bonabi, Esat Zarghami, Nosratollah Front Oncol Oncology BACKGROUND: Despite current therapies, lung cancer remains a global issue and requires the creation of novel treatment methods. Recent research has shown that biguanides such as metformin (MET) and silibinin (SIL) have a potential anticancer effect. As a consequence, the effectiveness of MET and SIL in combination against lung cancer cells was investigated in this study to develop an effective and novel treatment method. METHODS: Niosomal nanoparticles were synthesized via the thin-film hydration method, and field emission scanning electron microscopy (FE-SEM), Fourier transform infrared (FTIR), atomic force microscopy (AFM), and dynamic light scattering (DLS) techniques were used to evaluate their physico-chemical characteristics. The cytotoxic effects of free and drug-loaded nanoparticles (NPs), as well as their combination, on A549 cells were assessed using the MTT assay. An apoptosis test was used while under the influence of medication to identify the molecular mechanisms behind programmed cell death. With the use of a cell cycle test, it was determined whether pharmaceutical effects caused the cell cycle to stop progressing. Additionally, the qRT-PCR technique was used to evaluate the levels of hTERT, BAX, and BCL-2 gene expression after 48-h medication treatment. RESULTS: In the cytotoxicity assay, the growth of A549 lung cancer cells was inhibited by both MET and SIL. Compared to the individual therapies, the combination of MET and SIL dramatically and synergistically decreased the IC50 values of MET and SIL in lung cancer cells. Furthermore, the combination of MET and SIL produced lower IC50 values and a better anti-proliferative effect on A549 lung cancer cells. Real-time PCR results showed that the expression levels of hTERT and BCL-2 were significantly reduced in lung cancer cell lines treated with MET and SIL compared to single treatments (p< 0.001). CONCLUSION: It is anticipated that the use of nano-niosomal-formed MET and SIL would improve lung cancer treatment outcomes and improve the therapeutic efficiency of lung cancer cells. Frontiers Media S.A. 2023-08-17 /pmc/articles/PMC10471189/ /pubmed/37664043 http://dx.doi.org/10.3389/fonc.2023.1193708 Text en Copyright © 2023 Salmani-Javan, Jafari-Gharabaghlou, Bonabi and Zarghami https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Salmani-Javan, Elnaz
Jafari-Gharabaghlou, Davoud
Bonabi, Esat
Zarghami, Nosratollah
Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title_full Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title_fullStr Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title_full_unstemmed Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title_short Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
title_sort fabricating niosomal-peg nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471189/
https://www.ncbi.nlm.nih.gov/pubmed/37664043
http://dx.doi.org/10.3389/fonc.2023.1193708
work_keys_str_mv AT salmanijavanelnaz fabricatingniosomalpegnanoparticlescoloadedwithmetforminandsilibininforeffectivetreatmentofhumanlungcancercells
AT jafarigharabaghloudavoud fabricatingniosomalpegnanoparticlescoloadedwithmetforminandsilibininforeffectivetreatmentofhumanlungcancercells
AT bonabiesat fabricatingniosomalpegnanoparticlescoloadedwithmetforminandsilibininforeffectivetreatmentofhumanlungcancercells
AT zarghaminosratollah fabricatingniosomalpegnanoparticlescoloadedwithmetforminandsilibininforeffectivetreatmentofhumanlungcancercells